Latest

2 stories

Hide weekly roundups

Tuesday, September 29

Regulatory milestoneAtossa Therapeutics, Inc.

Atossa plans stapled CVR tied to rare pediatric disease review voucher

Atossa Therapeutics said its board approved a plan to give shareholders a contingent value right linked to future proceeds from a priority review voucher, capped at $50 million.

SEC filing

Friday, August 7

Quarterly updateAtossa Therapeutics, Inc.endoxifen

Atossa reports Q2 2026 results, completes enrollment in EVANGELINE trial

Atossa Therapeutics said enrollment finished in its Phase 2 breast cancer trial of (Z)-endoxifen and raised up to $16.5 million in a registered direct offering.

SEC filing